Takeda – Rusfertide US Rights Deal

Summary Protagonist Therapeutics has opted out of its 50:50 US profit-sharing agreement with Takeda for rusfertide, granting Takeda full US commercial rights in exchange for up to $475 million in near-term payments and substantial downstream milestones and royalties. What Happened Protagonist exercised its contractual opt-out…